PMID- 30168182
OWN - NLM
STAT- MEDLINE
DCOM- 20191231
LR  - 20191231
IS  - 1097-4644 (Electronic)
IS  - 0730-2312 (Linking)
VI  - 120
IP  - 1
DP  - 2019 Jan
TI  - Histamine H1 receptor gene polymorphism acts as a biological indicator of the 
      prediction of therapeutic efficacy in patients with allergic rhinitis in the 
      Chinese Han population.
PG  - 164-170
LID - 10.1002/jcb.27278 [doi]
AB  - H1-antihistamine has been shown to be effective in treating patients with 
      allergic rhinitis (AR), but its mechanism is still uncertain. We investigated 
      effects of histamine H1 receptor (HRH1) gene polymorphisms on the efficacy of 
      oral H1-antihistamine in perennial patients with AR caused by mites in the 
      Chinese Han population for the first time. A total of 224 Han Chinese patients 
      with AR and 165 Han Chinese healthy volunteers were selected. Genotype and allele 
      frequency distribution of -17C/T in HRH1 gene in patients with AR, serum levels 
      of eosinophil cationic protein (ECP), total immunoglobulin E (IgE), and specific 
      IgE were detected. The clinical symptoms of patients with AR were evaluated with 
      visual analogue scale (VAS). Direct counting method was applied to calculate 
      genotype and allele frequencies. Higher levels of serum ECP and total IgE were 
      shown in the AR group. Moreover, patients with CT, TT, or CT+TT genotype 
      increased the risk of AR incidence in the in the -17C/T site of HRH1, and CC 
      genotype and CT+TT genotype were associated with gender, asthma, VAS score, total 
      IgE level, and specific IgE level in patients with AR. In addition, oral 
      administration of H1-antihistamines improves clinical symptoms of patients with 
      AR. At last, patients with the CC genotype showed the increased efficacy of 
      H1-antihistamines in patients with AR. Our study provides evidence that HRH1 gene 
      polymorphisms may correlate with oral H1-antihistamine efficacy for the treatment 
      of patients with AR, which can be used as a biological indicator of the 
      prediction of therapeutic efficacy of patients with AR.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Chu, Jin-Tao
AU  - Chu JT
AUID- ORCID: 0000-0002-1861-5519
AD  - Department of Ears, Nose, and Throat, Weihai Central Hospital, Weihai, China.
LA  - eng
PT  - Journal Article
DEP - 20180830
PL  - United States
TA  - J Cell Biochem
JT  - Journal of cellular biochemistry
JID - 8205768
RN  - 0 (Environmental Biomarkers)
RN  - 0 (Histamine H1 Antagonists)
RN  - 0 (Phthalazines)
RN  - 0 (Receptors, Histamine H1)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 3.1.27.- (Eosinophil Cationic Protein)
RN  - EC 3.1.27.- (RNASE3 protein, human)
RN  - ZQI909440X (azelastine)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Asthma/genetics
MH  - Child
MH  - China
MH  - Environmental Biomarkers/*genetics
MH  - Eosinophil Cationic Protein/blood
MH  - Female
MH  - Gene Frequency/genetics
MH  - Genotype
MH  - Histamine H1 Antagonists/administration & dosage/*therapeutic use
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Male
MH  - Middle Aged
MH  - Phthalazines/administration & dosage/*therapeutic use
MH  - *Polymorphism, Single Nucleotide
MH  - Receptors, Histamine H1/*genetics
MH  - Rhinitis, Allergic/*drug therapy/*genetics
MH  - Sex Factors
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - H1-antihistamine
OT  - allergic rhinitis (AR)
OT  - efficacy
OT  - histamine H1 receptor (HRH1)
OT  - polymorphism
EDAT- 2018/09/01 06:00
MHDA- 2020/01/01 06:00
CRDT- 2018/09/01 06:00
PHST- 2018/01/17 00:00 [received]
PHST- 2018/06/22 00:00 [accepted]
PHST- 2018/09/01 06:00 [pubmed]
PHST- 2020/01/01 06:00 [medline]
PHST- 2018/09/01 06:00 [entrez]
AID - 10.1002/jcb.27278 [doi]
PST - ppublish
SO  - J Cell Biochem. 2019 Jan;120(1):164-170. doi: 10.1002/jcb.27278. Epub 2018 Aug 
      30.